Screener
Vir Biotechnology, Inc. VIR Total cash, cash equivalents and investments
Total cash, cash equivalents and investments at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:CashCashEquivalentsAndInvestments.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
As of June 30, 2026, the Company had approximately $1.01 billion in cash, cash equivalents, and investments, which the Company believes would be sufficient to fund its operations for a period through at least twelve months from the issuance date of these unaudited condensed consolidated financial statements. The Company also had approximately $8.9 million in restricted cash and cash equivalents as of June 30, 2026.
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s total cash, cash equivalents and investments?
- Vir Biotechnology, Inc. (VIR) reported total cash, cash equivalents and investments of $1.01B in Q2 2026.
- How has Vir Biotechnology, Inc.'s total cash, cash equivalents and investments changed year-over-year?
- Vir Biotechnology, Inc.'s total cash, cash equivalents and investments increased by 13.0% year-over-year, from $892.12M to $1.01B.
- What does total cash, cash equivalents and investments mean?
- Total cash, cash equivalents and investments as reported by Vir Biotechnology, Inc. Common Stock.
Ask your AI about Vir Biotechnology, Inc.'s total cash, cash equivalents and investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude